Tizanidine Tablet
Product Images NDC 16714-171

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 16714-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Tizanidine Tablets, USP 2 mg tablet label with NDC 16714-171-01, containing 150 tablets. The label states that the product is not interchangeable with Tizanidine capsules. It includes storage instructions, manufacturer information for Northstar Rx LLC Memphis, TN, and Dr. Reddy's Laboratories Limited, India, along with a barcode.*

FDA Label Image

Container2 (Container2)

Label for Tizanidine Tablets USP 4 mg oral tablets, supplied in a package of 150 tablets. The label states these tablets are not interchangeable with Tizanidine Capsules. Manufactured for NorthStar Rx LLC and by Dr. Reddy's Laboratories Limited, India. Includes storage instructions, manufacturer details, and barcode.*

FDA Label Image

Fig1 (Fig1)

A pharmacokinetic plot showing plasma Tizanidine concentration (ng/mL) over time (hours) after dosing. The graph compares 2 x 4 mg Tizanidine tablets and capsules taken with and without food, illustrating their concentration profiles up to 24 hours post-dose.*

FDA Label Image

Fig2 (Fig2)

Line graph showing improvement in Ashworth score over time after dosing with 16 mg and 8 mg tizanidine compared to placebo. The x-axis represents hours post-dose from 0 to 6, and the y-axis shows improvement in Ashworth score ranging from 0 to -5. The chart illustrates greater improvement with higher tizanidine dose and limited changes with placebo.*

FDA Label Image

Fig3 (Fig3)

A clinical study line graph comparing tizanidine (mean dose 28.8 mg) versus placebo on improvement in Ashworth score over time. The x-axis shows three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The y-axis measures improvement with values from -6 to 2. Data points include mean improvements with error bars for both tizanidine and placebo groups at each time point.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Tizanidine hydrochloride displaying its molecular arrangement, including aromatic and heterocyclic rings with chlorine and amino groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.